SCHEMBL12907425

SCHEMBL12907425

Cc1n[nH]c2cc(-c3ccccc3Oc3ccccc3)ccc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 3/20 0.48
▸ KDR P35968 3/20 0.48
▸ CDK4 P11802 2/20 0.48
▸ CCNA2 P20248 2/20 0.48
▸ CCND1 P24385 2/20 0.48
▸ CDK2 P24941 2/20 0.48
▸ CCND3 P30281 2/20 0.48
▸ BRD4 O60885 4/20 0.46
▸ SCN9A Q15858 2/20 0.45
▸ SCN5A Q14524 1/20 0.45
▸ PTGS2 P35354 1/20 0.44
▸ ABL1 P00519 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ TNKS2 Q9H2K2 1/20 0.42
▸ JAK2 O60674 1/20 0.41
▸ FGFR1 P11362 2/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41
▸ FFAR4 Q5NUL3 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12907412 0.90 BRD4 (0.46) CHEK1KDRCDK4CCNA2CCND1
SCHEMBL12907191 0.85 JAK2 (0.60) CHEK1KDRCDK4CCNA2CCND1
SCHEMBL12907469 0.83 JAK2 (0.53) CHEK1KDRCDK4CCNA2CCND1
SCHEMBL16576449 0.79 KDR (0.59) CHEK1KDRCDK4CCND1CCND3
SCHEMBL12907173 0.77 JAK2 (0.60) KDRCDK2SCN9ASCN5AJAK2
SCHEMBL12907457 0.77 JAK2 (0.67) CHEK1KDRCDK4CCNA2CCND1
SCHEMBL12907427 0.76 QPCT (0.49) CHEK1KDRCDK4CCNA2CCND1
SCHEMBL27805305 0.75 CHEK1 (0.43) CHEK1KDRFGFR1
SCHEMBL12907442 0.73 TRPA1 (0.60) SCN9ASCN5A
SCHEMBL18190547 0.72 BRD4 (0.50) BRD4PTGS2ABL1TNKS2FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7872039-B2 N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents MERCK PATENT GESELLSCHAFT (DE) 2011-01-18 — — US disclosed
Send feedback